Previous 10 |
home / stock / mnkkq / mnkkq news
Mallinckrodt Announces Data from a Multicenter Post Hoc Analysis of Terlipressin in Patients with Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI) at The Liver Meeting Digital Experience U.K. retrospective chart review examined potential predictors of treatment response includ...
Mallinckrodt Initiates Retrospective Study of the Use of Inhaled Nitric Oxide in COVID-19 Patients - Chart review is expected to collect real-world data on patients with respiratory complications associated with COVID-19 who received INOmax® (nitric oxide) gas, for inhalati...
Mallinckrodt Announces Data at Kidney Week 2020 Reimagined that Showed A Potential for Reduced Need for Renal Replacement (RRT) Therapy for Patients with Hepatorenal Syndrome Type 1 (HRS-1) Treated with Terlipressin Post-hoc, pooled analyses of three Phase 3 trials found HRS-1 p...
News, Short Squeeze, Breakout and More Instantly...
MALLINCKRODT TO REPORT EARNINGS RESULTS FOR SECOND QUARTER 2022 AND PROVIDE BUSINESS UPDATE PR Newswire DUBLIN , Aug. 3, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKPF), a global specialty pharmaceutical company, announced today that it wil...
Mallinckrodt Emerges from Chapter 11 with Strengthened Balance Sheet and Enhanced Financial Flexibility PR Newswire Appoints Sigurdur Olafsson as President and Chief Executive Officer DUBLIN, Ireland , June 16, 2022 /PRNewswire/ -- Mallinckr...
Mallinckrodt Announces Resubmission of Terlipressin to the FDA for the Treatment of Hepatorenal Syndrome PR Newswire DUBLIN , June 13, 2022 /PRNewswire/ -- Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, today announced the ...